Previous 10 | Next 10 |
2023-04-04 08:58:11 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Caribou Biosciences' ( NASDAQ: CRBU ) allogeneic CAR-T cell therapy CB-011 to treat relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in a phase 1 tri...
-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Fo...
-- CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection -- -- CB-011 is Caribou’s second program to enter the clinic from its off-the-shelf CAR-T cell therapy platform -- BERKELEY, Calif., March 29, 2023 (GLO...
-- CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients -- -- Next ANTLER update planned for H2 2023 -- BERKELEY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU...
New York, New York--(Newsfile Corp. - March 23, 2023) - Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. The lawsuit on behalf of Caribou investors has been commenced in the the United St...
New York, New York--(Newsfile Corp. - March 13, 2023) - Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. The lawsuit on behalf of Caribou investors has been commenced in the the United St...
2023-03-10 03:33:29 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q4 GAAP EPS of -$0.44 beats by $0.02 . Revenue of $3.7M (+44.5% Y/Y) beats by $0.63M . Caribou had $317.0M in cash, cash equivalents, and marketable securities as of December 31, 2022, co...
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 -- -- $317.0 ...
BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in...
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares. Investors who suffered losses in excess of $200,000 with shares of Caribou Biosciences, Inc. (NASDAQ: CRB...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today a...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...